Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Women’s plus-size apparel retailer Torrid Holdings (NYSE:CURV) fell by 36.4% on Wednesday after the company announced a ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

I’m in London, and I just paid for this damn fat drug I take. I said, it’s not working. They said, he said, I just paid $88 ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's ...

The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.

This growth stock experienced a significant decline in stock price following an announcement with a key partner. *Stock prices used were the afternoon prices of June 23, 2025. The video was published ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 14 stocks Jim Cramer recently shared insights on. Discussing the ...